NASDAQ · OCGN

Ocugen, Inc.

$1.21 -$0.06 (-4.72%) 1D After hours

Key Metrics

$429.92M
Market cap
P/E · TTM
$4.47M
Revenue · TTM
−$71.67M
Net income
EPS · TTM $-0.25
Dividend yield
Free cash flow −$59.58M
Beta · 1Y 1.41
EBITDA · TTM −$68.78M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 16
    From its Mar 13 high, the share price fell 52%.

    Peak close $2.48 on Mar 13; trough close $1.18 on Jun 16. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -52%
  • May 5
    The stock moved -19.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 5
  • Mar 11
    The stock moved +29.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$429.92M
Enterprise value$427.22M
Shares outstanding338.5M
52-wk range$0.93 – $2.73
Avg volume · 20D14.3M
Net cash $2.71M
Book value / share$0.02
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Ocugen, Inc.
IPO dateDec 3, 2014
Employees116

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S96.29
P/FCF
EV/EBITDA
EV/Sales95.68
Graham №

Profitability

Gross
Operating -1,594.3%
Net -1,605.2%
FCF -1,334.3%
ROE / ROIC -404.5% · —

Financial Health

Current ratio1.86
Quick ratio
Debt / equity5.03
Debt / EBITDA -0.42
Net cash $2.71M
Working capital$17.84M

Cash Flow · TTM

Operating CF −$59.40M
Capex −$175.00K
Free cash flow −$59.58M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-9.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings